Market Overview:
Gastritis refers to inflammation or irritation of the lining of the stomach. Common symptoms of gastritis include abdominal pain, bloating, nausea, and vomiting. Gastritis is often caused by Helicobacter pylori infection, excessive alcohol consumption, smoking, stress, and certain medications. Treatment of gastritis primarily focuses on minimizing symptoms, protecting the stomach lining, and eradicating the underlying cause. Main treatment options include antacids, H2 blockers, proton pump inhibitors, and antibiotics. The gastritis treatment market is estimated at USD 131.76 billion in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023-2030, as highlighted in a
new report published by Coherent Market Insights. I am. Key Market Trends: Rising incidence of gastric ulcers is the key factor driving the growth of the gastritis treatment market. A gastric ulcer is an open ulcer or lesion that forms on the lining of the stomach. Changes in lifestyle and dietary habits have led to a significant increase in cases of gastric ulcers worldwide. According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 4 million Americans suffer from acute stomach ulcers each year. As age is the main risk factor for gastric disease, the increasing elderly population also contributes to the high prevalence of gastritis. Additionally, increasing consumption of non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief has emerged as one of the major causes of gastritis, supporting the market growth during the forecast period. Porter’s Analysis Threat of New Entrants: The threat of new entrants is low as the gastritis treatment market requires significant R&D investments and established distribution network. Bargaining power of the buyer: The bargaining power of the buyer is high due to the availability of generic drugs and alternative treatments. Bargaining power of suppliers: Suppliers have moderate bargaining power due to the presence of many suppliers and availability of raw materials. Threat of new substitutes: The threat of substitutes is moderate as alternative treatment options are available. Competitiveness: High due to presence of many global and local players. SWOT Analysis Strengths: A wide range of treatment options are available and healthcare costs are increasing. Access and availability of OTC medicines. Weaknesses: The presence of alternative gastroprotective agents and disease recurrence affect treatment compliance. Side effects associated with some drugs. Opportunities: Growth in emerging markets, increasing elderly population susceptible to gastritis. New product launches focused on disease-specific treatments. Threats: Patent cliff for major drugs, price pressure from regulators, and growing popularity of herbal remedies. Key Points The global gastritis treatment market is expected to witness high growth, exhibiting a CAGR of 6.2% during the forecast period, due to increase in alcohol consumption, smoking, and stress levels among individuals. The market size in 2023 is USD 131.76 billion. Regionally, North America dominated the market with over 30% share in 2023 due to increasing adoption of advanced treatment options and rising healthcare costs. Asia-Pacific is expected to register the fastest CAGR during the forecast period due to rising healthcare awareness and increasing discretionary spending in developing countries. The major companies operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, and Takeda Pharmaceutical Company Limited. Pfizer dominates the market with its broad product portfolio of proton pump inhibitors aimed at treating a variety of gastric diseases.